(Q45066154)

9 December 2017

title

Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma (English)

1 reference

Hormone Replacement Therapy

9 December 2017

main subject

1 reference

1 reference

6

1 reference

9 December 2017

2

Susan E Hankinson

1 reference

9 December 2017

4

Bernard A Rosner

1 reference

9 December 2017

3

Stuart J Schnitt

1 reference

9 December 2017

5

Michelle D Holmes

1 reference

9 December 2017

Wendy Y Chen

1

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

1 reference

9 December 2017

volume

101

1 reference

9 December 2017

issue

7

1 reference

9 December 2017

page(s)

1490-1500

1 reference

Bias in breast cancer analyses due to error in age at menopause.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Hormone replacement therapy in relation to breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Prognostic characteristics in breast cancers after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Test of the National Death Index and Equifax Nationwide Death Search.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Reproducibility and validity of self-reported menopausal status in a prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

A Prospective Study of Folate Intake and the Risk of Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Trends in incidence rates of invasive lobular and ductal breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Tumour development, histology and grade of breast cancers: Prognosis and progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Aggressiveness of screen-detected breast cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Breast cancer in New South Wales in 1972-1995: tumor size and the impact of mammographic screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Breast cancers found by screening: earlier detection, lower malignant potential or both?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Estrogen receptors and distinct patterns of breast cancer relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20499

7 January 2021

Identifiers

DOI

10.1002/CNCR.20499

1 reference

9 December 2017

1 reference